Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10543846 | 0.90 | MAOB (0.61) | MAOBSMN1; SMN2LMNAHPGDALOX15 | |
| SCHEMBL477599 | 0.88 | SMN1; SMN2 (0.62) | MAOBSMN1; SMN2LMNAHPGDALOX15 | |
| SCHEMBL9367608 | 0.84 | MAOB (0.68) | MAOBSMN1; SMN2TSHRMAPK1KMT2A | |
| SCHEMBL17064305 | 0.83 | MAOB (0.71) | MAOBSMN1; SMN2LMNAHPGDALOX15 | |
| SCHEMBL31067669 | 0.83 | MAOB (0.71) | MAOBSMN1; SMN2LMNAHPGDALOX15 | |
| SCHEMBL791569 | 0.82 | MAOB (1.00) | MAOBMRGPRX4APPBCHE | |
| SCHEMBL4822561 | 0.82 | AOC3 (0.54) | TSHRMAPK1 | |
| SCHEMBL4707722 | 0.82 | ALOX5 (0.59) | MAOBSMN1; SMN2LMNAHPGDALOX15 | |
| SCHEMBL7713126 | 0.82 | SMN1; SMN2 (0.56) | MAOBSMN1; SMN2LMNAHPGDALOX15 | |
| SCHEMBL6202972 | 0.81 | MAOB (0.59) | MAOBSMN1; SMN2LMNAHPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470723-B2 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080114061-A1 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION | 2008-05-15 | — | — | US | disclosed |
| US-7312241-B2 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| CN-101053558-A | Diphenylethylene compounds and uses thereof | CELGENE CORP (US) | 2007-10-17 | — | — | CN | disclosed |
| CN-101056846-A | Diphenylethylene compounds and uses thereof | CELGENE CORP (US) | 2007-10-17 | — | — | CN | disclosed |
| EP-1799634-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1603864-A4 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORP (US) | 2007-04-11 | — | — | EP | disclosed |
| CN-1780811-A | Diphenylethylene compounds and uses thereof | CELGENE CORP (US) | 2006-05-31 | — | — | CN | disclosed |
| WO-2006026747-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1603864-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050107339-A1 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION | 2005-05-19 | — | — | US | disclosed |
| US-20050014727-A1 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION | 2005-01-20 | — | — | US | disclosed |
| WO-2004078144-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107339-A1 | Diphenylethylene compounds and uses thereof | VHL, TNF, PTGES | MAOB 2053/4885SMN1; SMN2 2969/4885LMNA 2114/4885 |
| US-20080114061-A1 | Diphenylethylene compounds and uses thereof | VHL, TNF, PTGES | MAOB 2053/4885SMN1; SMN2 2969/4885LMNA 2114/4885 |
| US-20050014727-A1 | Diphenylethylene compounds and uses thereof | VHL, TNF, PTGES | MAOB 2053/4885SMN1; SMN2 2969/4885LMNA 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.